Program
azvudine
Also written as “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)” and “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”.
Its studies are mostly in COVID-19 · Renal Insufficiency, led by 2 companies.
Drug pageAzvudine: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Henan Genuine Biotech | 81 open or running | phase 1since May 8, 2025 | May 8, 2025 | none ahead |
| Fosun Pharmaits history only | 20 open or running | phase 3since Nov 30, 2022 | Nov 30, 2022 | none ahead |
Also a collaborator on its studies: HeNan Sincere Biotech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Henan Genuine Biotech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2025First studies: 8 phase 1 studiesFirst studyNCT06991634, NCT07002281, NCT07002255 and 5 more
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 8 Henan Genuine Biotech leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07001501Healthy · China | 1 | Completed | Apr 25, 2022 | 15 |
| NCT07001488Healthy · China | 1 | Completed | May 1, 2022 | 15 |
| NCT07001436Renal Insufficiency · China | 1 | Recruiting | Aug 30, 2025 | 40 |
| NCT07002281Healthy · China | 1 | Completed | Oct 10, 2024 | 6 |
| NCT07002255Healthy · China | 1 | Completed | Mar 22, 2022 | 15 |
| NCT07002242Healthy · China | 1 | Completed | Aug 25, 2022 | 15 |
| NCT07002229Healthy · China | 1 | Completed | Feb 23, 2022 | 15 |
| NCT06991634Healthy · China | 1 | Completed | Apr 27, 2023 | 24 |
How it is read
Names in the registry
- “Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)”, 3 entries
- “Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)”, 3 entries
- “Azvudine tablets(FNC) and Rifampicin Capsules (RIF)”, 3 entries
- “Azvudine tablets”, 2 entries
- “Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)”, 2 entries
Conditions, from the studies’ own filings
- COVID-19, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.